Gynecologic Oncology Reports最新文献

英文中文

Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2025.101680

Salamatu Abdul-Aziz , Nawaraj Bhattarai , Luke Vale , Gurdeep S Sagoo , Asima Mukhopadhyay

Ovarian cancer (OC) poses a significant socio-economic burden globally with the greatest impact observed in low-and-middle income countries (LMIC). Despite the survival benefit from targeted therapies such as bevacizumab and poly (ADP- ribose) polymerase (PARP) inhibitors, they are associated with high costs to patients and payers which widens the disparities between high and low-income countries. OC treatments may also cause significant morbidity from cytoreductive surgery through to the use of targeted therapies reducing quality of life (QoL). Innovative approaches are necessary to address the increasing burden from the cost and morbidity of OC treatment especially in LMIC. De-escalation of treatment without compromising oncological outcomes could be a strategy to reduce financial cost and morbidity. Moreover, de-escalation techniques integrating the knowledge of pharmacokinetics and pharmacodynamics for dose reduction should be incorporated into clinical trials to identify the minimum effective dose rather than the maximum tolerated with the goal of reducing clinical and financial toxicity. This review summarises the health and economic burden of ovarian cancer with particular reference to LMIC and proposes de-escalation of targeted therapy as a clinical and economic strategy in increasing accessibility and affordability with consideration of patient preferences.

{"title":"Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer","authors":"Salamatu Abdul-Aziz , Nawaraj Bhattarai , Luke Vale , Gurdeep S Sagoo , Asima Mukhopadhyay","doi":"10.1016/j.gore.2025.101680","DOIUrl":"10.1016/j.gore.2025.101680","url":null,"abstract":"<div><div>Ovarian cancer (OC) poses a significant socio-economic burden globally with the greatest impact observed in low-and-middle income countries (LMIC). Despite the survival benefit from targeted therapies such as bevacizumab and poly (ADP- ribose) polymerase (PARP) inhibitors, they are associated with high costs to patients and payers which widens the disparities between high and low-income countries. OC treatments may also cause significant morbidity from cytoreductive surgery through to the use of targeted therapies reducing quality of life (QoL). Innovative approaches are necessary to address the increasing burden from the cost and morbidity of OC treatment especially in LMIC. De-escalation of treatment without compromising oncological outcomes could be a strategy to reduce financial cost and morbidity. Moreover, de-escalation techniques integrating the knowledge of pharmacokinetics and pharmacodynamics for dose reduction should be incorporated into clinical trials to identify the minimum effective dose rather than the maximum tolerated with the goal of reducing clinical and financial toxicity. This review summarises the health and economic burden of ovarian cancer with particular reference to LMIC and proposes de-escalation of targeted therapy as a clinical and economic strategy in increasing accessibility and affordability with consideration of patient preferences.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101680"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vulvar keratoacanthoma may be a malignant precursor: A case report and literature review

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2024.101674

Fang Chen , Yang Wang , Dina Haishaer , Feng Bai

Background

Keratoacanthoma is a relatively rare skin tumor, with vulvar keratoacanthoma being even more uncommon. Although the majority of keratoacanthomas exhibit a benign course, a subset of cases may show features of malignant potential, such as marginal invasion and recurrence.

Case

An 82-year-old female presented with a rapidly growing exophytic lesion on the left vulva, measuring 1.5 cm in diameter, accompanied by pruritus. The lesion had been present for two months. The patient underwent vulvar mass excision, and postoperative pathology revealed squamous cell hyperplasia with glassy cytoplasm and no significant cellular atypia. The surgical margins were clear. Three years later, the tumor recurred with disordered growth.

Conclusion

In terms of histological and clinical presentation, keratoacanthoma may overlap with classical well-differentiated squamous cell carcinoma. In rare cases, certain atypical keratoacanthomas may exhibit intravascular and perineural invasion, along with lymph node metastasis. By sharing our treatment experience of a patient with recurrent vulvar keratoacanthoma following surgery, we aim to provide a cautionary perspective for the clinical management of such cases.

{"title":"Vulvar keratoacanthoma may be a malignant precursor: A case report and literature review","authors":"Fang Chen , Yang Wang , Dina Haishaer , Feng Bai","doi":"10.1016/j.gore.2024.101674","DOIUrl":"10.1016/j.gore.2024.101674","url":null,"abstract":"<div><h3>Background</h3><div>Keratoacanthoma is a relatively rare skin tumor, with vulvar keratoacanthoma being even more uncommon. Although the majority of keratoacanthomas exhibit a benign course, a subset of cases may show features of malignant potential, such as marginal invasion and recurrence.</div></div><div><h3>Case</h3><div>An 82-year-old female presented with a rapidly growing exophytic lesion on the left vulva, measuring 1.5 cm in diameter, accompanied by pruritus. The lesion had been present for two months. The patient underwent vulvar mass excision, and postoperative pathology revealed squamous cell hyperplasia with glassy cytoplasm and no significant cellular atypia. The surgical margins were clear. Three years later, the tumor recurred with disordered growth.</div></div><div><h3>Conclusion</h3><div>In terms of histological and clinical presentation, keratoacanthoma may overlap with classical well-differentiated squamous cell carcinoma. In rare cases, certain atypical keratoacanthomas may exhibit intravascular and perineural invasion, along with lymph node metastasis. By sharing our treatment experience of a patient with recurrent vulvar keratoacanthoma following surgery, we aim to provide a cautionary perspective for the clinical management of such cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101674"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular characterization of ovarian mesonephric-like adenocarcinoma: Insights from single-cell RNA sequencing and mitochondrial metabolism

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2024.101670

Gwan Hee Han , Ye-Ah Kim , Hyunjin Park , Hee Yun , Jae-Hoon Kim , Man S. Kim , Hanbyoul Cho

Objectives

Ovarian mesonephric-like adenocarcinoma (MLA) is a rare malignancy with limited understanding of its molecular features and therapeutic vulnerabilities. Although similar to uterine MLA, its unique characteristics remain undefined. This study aimed to characterize ovarian MLA using single-cell RNA sequencing (scRNA-seq) and compare it with high-grade serous ovarian cancer (HGSOC).

Methods

We analyzed the cellular and molecular heterogeneity of an ovarian MLA sample using scRNA-seq. Differential gene expression and pathway analyses were performed to identify unique molecular signatures and therapeutic targets. HGSOC scRNA-seq datasets were used for comparative analysis.

Results

Ovarian MLA demonstrated reduced heterogeneity, with a predominance of epithelial cells compared to HGSOC. Transcriptomic profiling revealed an upregulation of mitochondrial metabolism and lipid biosynthesis genes, indicating a metabolic shift toward oxidative phosphorylation. Gene enrichment and protein–protein interaction analyses identified distinct pathways, including mitochondrial biogenesis and dynamics, suggesting mitochondrial reprogramming.

Conclusions

This study provides the first scRNA-seq-based molecular characterization of ovarian MLA, differentiating it from HGSOC. Findings suggest potential therapeutic avenues, with a proposed combination therapy targeting MAP kinase and PI3K/AKT/mTOR pathways. Validation in larger cohorts is necessary for clinical application.

{"title":"Molecular characterization of ovarian mesonephric-like adenocarcinoma: Insights from single-cell RNA sequencing and mitochondrial metabolism","authors":"Gwan Hee Han , Ye-Ah Kim , Hyunjin Park , Hee Yun , Jae-Hoon Kim , Man S. Kim , Hanbyoul Cho","doi":"10.1016/j.gore.2024.101670","DOIUrl":"10.1016/j.gore.2024.101670","url":null,"abstract":"<div><h3>Objectives</h3><div>Ovarian mesonephric-like adenocarcinoma (MLA) is a rare malignancy with limited understanding of its molecular features and therapeutic vulnerabilities. Although similar to uterine MLA, its unique characteristics remain undefined. This study aimed to characterize ovarian MLA using single-cell RNA sequencing (scRNA-seq) and compare it with high-grade serous ovarian cancer (HGSOC).</div></div><div><h3>Methods</h3><div>We analyzed the cellular and molecular heterogeneity of an ovarian MLA sample using scRNA-seq. Differential gene expression and pathway analyses were performed to identify unique molecular signatures and therapeutic targets. HGSOC scRNA-seq datasets were used for comparative analysis.</div></div><div><h3>Results</h3><div>Ovarian MLA demonstrated reduced heterogeneity, with a predominance of epithelial cells compared to HGSOC. Transcriptomic profiling revealed an upregulation of mitochondrial metabolism and lipid biosynthesis genes, indicating a metabolic shift toward oxidative phosphorylation. Gene enrichment and protein–protein interaction analyses identified distinct pathways, including mitochondrial biogenesis and dynamics, suggesting mitochondrial reprogramming.</div></div><div><h3>Conclusions</h3><div>This study provides the first scRNA-seq-based molecular characterization of ovarian MLA, differentiating it from HGSOC. Findings suggest potential therapeutic avenues, with a proposed combination therapy targeting MAP kinase and PI3K/AKT/mTOR pathways. Validation in larger cohorts is necessary for clinical application.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101670"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adenoid basal cell carcinoma: An underrecognized cervical malignancy 腺样基底细胞癌：一种未被充分认识的宫颈恶性肿瘤。

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2024.101667

Arielle Katcher , Juliana Schilsky , Alisha Daroch , Tahyna Hernandez , Andrew Menzin , Lisa Dos Santos , Jill Whyte , Marina Frimer

Introduction

Adenoid basal cell carcinoma is a rare cervical malignancy which is indolent in nature but resembles more commonly occurring aggressive malignancies.

Cases

Here we describe three cases of cervical adenoid basal cell carcinoma. All patients had a history of cervical dysplasia with high-risk HPV. The first and second patient were treated with hysterectomy, and the third patient opted for surveillance after cold knife conization. All patients have no evidence of disease to date.

Conclusion

Cervical adenoid basal cell carcinoma is a rare malignancy that requires careful diagnostic attention due to its histologic similarities to more aggressive malignancies and the risk of misclassification. Advances in diagnostic criteria including immunohistochemistry (IHC) classification are key to distinguishing this unique pathological entity. Definitive treatment depends on accurate diagnosis. Optimal treatment involves surgical management with hysterectomy and lymph node assessment. Excisional biopsy with thorough pathologic evaluation for invasive carcinoma can be considered in patients who desire future fertility.

腺样基底细胞癌是一种罕见的宫颈恶性肿瘤，本质上是惰性的，但类似于更常见的侵袭性恶性肿瘤。病例：我们在此报告三例宫颈腺样基底细胞癌。所有患者均有宫颈发育不良伴高危HPV病史。第1、2例患者行子宫切除术，第3例患者冷刀切腹后继续观察。到目前为止，所有患者均无发病证据。结论：宫颈腺样基底细胞癌是一种罕见的恶性肿瘤，由于其在组织学上与其他侵袭性恶性肿瘤相似，且有误诊的危险，需要仔细诊断。包括免疫组织化学（IHC）分类在内的诊断标准的进步是区分这种独特病理实体的关键。最终的治疗取决于准确的诊断。最佳治疗包括手术治疗，子宫切除术和淋巴结评估。对于希望将来生育的患者，可以考虑对浸润性癌进行切除活检并进行彻底的病理评估。

{"title":"Adenoid basal cell carcinoma: An underrecognized cervical malignancy","authors":"Arielle Katcher , Juliana Schilsky , Alisha Daroch , Tahyna Hernandez , Andrew Menzin , Lisa Dos Santos , Jill Whyte , Marina Frimer","doi":"10.1016/j.gore.2024.101667","DOIUrl":"10.1016/j.gore.2024.101667","url":null,"abstract":"<div><h3>Introduction</h3><div>Adenoid basal cell carcinoma is a rare cervical malignancy which is indolent in nature but resembles more commonly occurring aggressive malignancies.</div></div><div><h3>Cases</h3><div>Here we describe three cases of cervical adenoid basal cell carcinoma. All patients had a history of cervical dysplasia with high-risk HPV. The first and second patient were treated with hysterectomy, and the third patient opted for surveillance after cold knife conization. All patients have no evidence of disease to date.</div></div><div><h3>Conclusion</h3><div>Cervical adenoid basal cell carcinoma is a rare malignancy that requires careful diagnostic attention due to its histologic similarities to more aggressive malignancies and the risk of misclassification. Advances in diagnostic criteria including immunohistochemistry (IHC) classification are key to distinguishing this unique pathological entity. Definitive treatment depends on accurate diagnosis. Optimal treatment involves surgical management with hysterectomy and lymph node assessment. Excisional biopsy with thorough pathologic evaluation for invasive carcinoma can be considered in patients who desire future fertility.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101667"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ocular surface disease related to tisotumab vedotin-tftv

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2025.101676

Daniella Lent-Schochet , Shachar Tauber , Zachary Seagrave , Grace L. Paley , Asim V. Farooq

Introduction

To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.

Methods

This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.

Results

Five patients were identified who developed ocular surface disease while on TV. All patients received a standard ocular adverse event prophylaxis regimen with each infusion per the product label, including a cool ocular compress, topical vasoconstrictor, topical steroid, and artificial tears. All five patients developed conjunctival subepithelial fibrosis. Two patients developed bilateral pseudomembranous conjunctivitis, one of whom subsequently developed conjunctival scarring. Two patients developed a bilateral culture positive conjunctivitis, which responded to topical antibiotics. One patient developed bilateral infectious keratitis and was treated with partial thickness corneal transplantation of both eyes.

Conclusion

TV can be associated with ocular surface disease, including conjunctival scarring and infectious keratitis. Some cases may require surgical intervention. Oncologists and ophthalmologists should be aware of the possibility of these ocular complications, especially as more ADCs are approved. Further studies are required to determine toxicity mechanisms as well as optimal prophylaxis and management strategies.

{"title":"Ocular surface disease related to tisotumab vedotin-tftv","authors":"Daniella Lent-Schochet , Shachar Tauber , Zachary Seagrave , Grace L. Paley , Asim V. Farooq","doi":"10.1016/j.gore.2025.101676","DOIUrl":"10.1016/j.gore.2025.101676","url":null,"abstract":"<div><h3>Introduction</h3><div>To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.</div></div><div><h3>Methods</h3><div>This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.</div></div><div><h3>Results</h3><div>Five patients were identified who developed ocular surface disease while on TV. All patients received a standard ocular adverse event prophylaxis regimen with each infusion per the product label, including a cool ocular compress, topical vasoconstrictor, topical steroid, and artificial tears. All five patients developed conjunctival subepithelial fibrosis. Two patients developed bilateral pseudomembranous conjunctivitis, one of whom subsequently developed conjunctival scarring. Two patients developed a bilateral culture positive conjunctivitis, which responded to topical antibiotics. One patient developed bilateral infectious keratitis and was treated with partial thickness corneal transplantation of both eyes.</div></div><div><h3>Conclusion</h3><div>TV can be associated with ocular surface disease, including conjunctival scarring and infectious keratitis. Some cases may require surgical intervention. Oncologists and ophthalmologists should be aware of the possibility of these ocular complications, especially as more ADCs are approved. Further studies are required to determine toxicity mechanisms as well as optimal prophylaxis and management strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101676"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rectal carcinoma presenting as vulvar metastasis: A case report

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2025.101681

Megan Gorman , Vanessa Ross , Lisa dos Santos , Shaza Al-Atassi , Marina Frimer

Introduction

Metastatic adenocarcinoma to the vulva is a rare phenomenon, with few cases reported in the literature. Here we discuss a 64-year-old woman with a history of colorectal adenocarcinoma presenting with a vulvar metastasis.

Methods

Clinical information was gathered via review of the electronic medical record.

Results

IHC is useful in diagnosis of unusual metastases. In this case, staining for CDx2, CK20, PAX8, and CK7 was helpful in distinguishing a gynecologic versus gastrointestinal primary.

Conclusion

Our case highlights the importance of an accurate and timely diagnosis of gynecologic metastases in patients with a history of colorectal cancer. Examiners should have a low threshold for biopsy and imaging when patients present with skin changes or vulvovaginal complaints. Appropriate treatment requires a multidisciplinary approach.

引用次数: 0

A novel MXI1-NUTM2B fusion detected in an undifferentiated ovarian cancer 在未分化卵巢癌中检测到一种新的MXI1-NUTM2B融合。

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2024.101653

Mohammed Elshafey, Malek Ghandour, Rebecca M. Adams, Daniel Neill, Radhika Gogoi

引用次数: 0

Cervicitis decidualis mimicking cervical cancer in pregnancy 宫颈蜕膜炎模仿妊娠期宫颈癌。

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2024.101663

Hooman Soleymani majd , Kezia Gaitskell , Catherine Johnson , Karin Hellner

Cervical decidual reaction in pregnancy is a common finding. In rare cases, these changes can mimic the appearance of invasive cervical cancers.

We are presenting a case of a pregnant woman with a large cervical mass. Whilst magnetic resonance imaging (MRI) supported a diagnosis of cervical cancer, cervical tissue biopsies showed decidual reaction and no invasion. Cervical appearance postpartum reverted back to normal. Importantly, cervical biopsies were obtained in a fully equipped theatre attended by multiple specialities in case of life-threatening haemorrhage during pregnancy.

妊娠期宫颈蜕膜反应是一种常见现象。在极少数情况下，这些变化可以模仿侵袭性宫颈癌的外观。我们报告一例孕妇宫颈肿块大的病例。虽然磁共振成像（MRI）支持宫颈癌的诊断，宫颈组织活检显示蜕膜反应，没有侵袭。产后宫颈外观恢复正常。重要的是，如果在怀孕期间发生危及生命的大出血，宫颈活检是在设备齐全的多专科医院进行的。

引用次数: 0

A Technique for Re-siting a Midline Transverse Loop Colostomy

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.gore.2024.101668

Nourah Ibrahim , Alon D. Altman

引用次数: 0

Readability assessment of Spanish online patient education materials in gynecologic oncology 西班牙语妇科肿瘤学在线患者教育材料的可读性评估。

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2024-12-01 DOI: 10.1016/j.gore.2024.101548

Dionna Thomas , Rubina Ratnaparkhi

Objective

Over half of Spanish-speaking patients use the internet to understand their diagnosis. We evaluated readability of Spanish online patient education materials (OPEMs) about gynecologic cancer to assess compliance with National Institute of Health (NIH) recommendations to be at or below eighth grade reading level.

Methods

We conducted an online search using six Spanish gynecologic cancer terms on three major search engines with cookies and location disabled. The first five results by cancer type were included. Readability was analyzed by Spanish Simple Measure of Gobbledygook (SMOG) and Gilliam-Peña-Mountain (GPM) indices. One-way ANOVA with Tukey’s Honestly Significant Difference (HSD) post-hoc analysis was performed.

Results

322 unique OPEMs were retrieved using Spanish queries. This included 132 (41 %) from non-profit organizations, 114 (35.4 %) from governmental organizations, and 63 (19.5 %) from academic medical centers; the remainder were from professional medical society or pharmaceutical company sources. Overall, gynecologic oncology OPEMs were written at a mean 9.8 ± 1.2 grade reading level. Only 14 % of OPEMs were written at or below an eighth grade reading level. There were significant differences in readability by publishing source (p < 0.001). Though there were no significant differences in readability by cancer type (p = 0.07), the mean reading level for all cancer types was between ninth and eleventh grade level.

Conclusions

86% of readily searchable Spanish gynecologic oncology OPEMs are written above recommended reading levels. Gynecologic oncologists should curate and support Spanish-speaking patients in finding high-quality online educational content.

目的：超过一半的西班牙语患者使用互联网来了解他们的诊断。我们评估了西班牙在线妇科癌症患者教育材料（OPEMs）的可读性，以评估是否符合美国国立卫生研究院（NIH）推荐的8年级阅读水平。方法：我们在三个主要的搜索引擎上使用六个西班牙妇科癌症术语进行了在线搜索，并禁用了cookie和位置。按癌症类型划分的前5个结果包括在内。采用西班牙语简易量表（Spanish Simple Measure of Gobbledygook， SMOG）和Gilliam-Peña-Mountain （GPM）指数分析可读性。采用单因素方差分析和HSD事后分析。结果：使用西班牙语查询检索了322个唯一的opem。其中，非营利机构132家（41%）、政府机构114家（35.4%）、学术医疗中心63家（19.5%）；其余来自专业医学协会或制药公司。总体而言，妇科肿瘤OPEMs的平均阅读水平为9.8±1.2级。只有14%的opem的写作达到或低于八年级的阅读水平。结论：86%易于检索的西班牙妇科肿瘤学OPEMs的写作水平高于推荐阅读水平。妇科肿瘤学家应该帮助讲西班牙语的患者找到高质量的在线教育内容。

{"title":"Readability assessment of Spanish online patient education materials in gynecologic oncology","authors":"Dionna Thomas , Rubina Ratnaparkhi","doi":"10.1016/j.gore.2024.101548","DOIUrl":"10.1016/j.gore.2024.101548","url":null,"abstract":"<div><h3>Objective</h3><div>Over half of Spanish-speaking patients use the internet to understand their diagnosis. We evaluated readability of Spanish online patient education materials (OPEMs) about gynecologic cancer to assess compliance with National Institute of Health (NIH) recommendations to be at or below eighth grade reading level.</div></div><div><h3>Methods</h3><div>We conducted an online search using six Spanish gynecologic cancer terms on three major search engines with cookies and location disabled. The first five results by cancer type were included. Readability was analyzed by Spanish Simple Measure of Gobbledygook (SMOG) and Gilliam-Peña-Mountain (GPM) indices. One-way ANOVA with Tukey’s Honestly Significant Difference (HSD) post-hoc analysis was performed.</div></div><div><h3>Results</h3><div>322 unique OPEMs were retrieved using Spanish queries. This included 132 (41 %) from non-profit organizations, 114 (35.4 %) from governmental organizations, and 63 (19.5 %) from academic medical centers; the remainder were from professional medical society or pharmaceutical company sources. Overall, gynecologic oncology OPEMs were written at a mean 9.8 ± 1.2 grade reading level. Only 14 % of OPEMs were written at or below an eighth grade reading level. There were significant differences in readability by publishing source (p < 0.001). Though there were no significant differences in readability by cancer type (p = 0.07), the mean reading level for all cancer types was between ninth and eleventh grade level.</div></div><div><h3>Conclusions</h3><div>86% of readily searchable Spanish gynecologic oncology OPEMs are written above recommended reading levels. Gynecologic oncologists should curate and support Spanish-speaking patients in finding high-quality online educational content.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101548"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Gynecologic Oncology Reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀